| Jamie L Puckett, MD | |
|
201 Bjc Saint Peters Dr, Suite 100, Saint Peters, MO 63376-3091 | |
| (636) 916-8200 | |
| (636) 946-8533 |
| Full Name | Jamie L Puckett |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 29 Years |
| Location | 201 Bjc Saint Peters Dr, Saint Peters, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164420477 | NPI | - | NPPES |
| 204809008 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 108740 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm St Joseph Hospital West | Lake saint louis, MO | Hospital |
| Barnes-jewish St Peters Hospital | Saint peters, MO | Hospital |
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boonslick Medical Group Inc | 3779481510 | 8 |
News Archive
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children's Autism Metabolome Project or CAMP.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
When you eat something super tasty, ever wonder why you really don't want to stop even though you know you've eaten enough? Scientists at the UNC School of Medicine may have found the reason.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
› Verified 2 days ago
| Entity Name | Boonslick Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588662803 PECOS PAC ID: 3779481510 Enrollment ID: O20040727000319 |
News Archive
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children's Autism Metabolome Project or CAMP.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
When you eat something super tasty, ever wonder why you really don't want to stop even though you know you've eaten enough? Scientists at the UNC School of Medicine may have found the reason.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jamie L Puckett, MD 201 Bjc Saint Peters Dr, Suite 100, Saint Peters, MO 63376-3091 Ph: (636) 916-8200 | Jamie L Puckett, MD 201 Bjc Saint Peters Dr, Suite 100, Saint Peters, MO 63376-3091 Ph: (636) 916-8200 |
News Archive
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across the country, report new findings from the Children's Autism Metabolome Project or CAMP.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
When you eat something super tasty, ever wonder why you really don't want to stop even though you know you've eaten enough? Scientists at the UNC School of Medicine may have found the reason.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
› Verified 2 days ago
Stephanie Higgins, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 107 Piper Hill Dr Ste 150, Saint Peters, MO 63376 Phone: 314-251-8966 | |
Kirim Chang, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 10 Hospital Dr, Saint Peters, MO 63376 Phone: 636-916-9376 | |
Dr. Megan Marie Mohrman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 209 First Executive Ave, Saint Peters, MO 63376 Phone: 636-936-8777 Fax: 636-939-4257 | |
Dr. Janet Matuszek, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 209 First Executive Ave, Saint Peters, MO 63376 Phone: 636-936-8777 Fax: 636-939-4257 | |
Evelyne G Schuetz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Bjc Saint Peters Dr, Suite 100, Saint Peters, MO 63376 Phone: 636-916-8200 Fax: 636-946-8533 |